FDA
-
-
-
-
-
-
-
Dyne Therapeutics submits FDA application for DMD treatment
-
-
-
-
-
-
-
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
-
-
-
-
-
-
-
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
-
-
-
-
-
-
-
Dyne Therapeutics receives orphan drug designation in Japan for DM1 treatment
-
-
-
-
-
-
-
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
-
-
-
-
-
-
-
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
-
-
-
-
-
-
-
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
325,464 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

